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Abstract 
Average bioequivalence is used to assess pharmacokinetic properties of proposed generic drug 
before they are marketed. The limitations of average bioequivalence have led the U.S. Food and 
Drug Administration to propose the use of popUlation bioequivalence and individual 
bioequivalence. In this study, bootstrap confidence intervals were used to evaluate population 
bioequivalence and individual bioequivalence in the context of a 2 x 4 crossover experimental 
design. Two bioequivalence criteria were compared: the mean-squared difference criterion and a 
probability-based criterion. Simulations were conducted to study the properties of the bootstrap 
confidence intervals under each criterion in establishing population bioequivalence or individual 
bioequivalence. Various inter-subject, within-subject, and subject-by-formulation interaction 
variance components were considered. 
1. Introduction 
Suppose that a generic drug T has been developed and is proposed as an alternative to the 
reference drug R. Before marketing formulation T, it must be determined whether the two drugs 
are bioequivalent. When two formulations of the same drug or two drug products are claimed to 
be bioequivalent, it is assumed that they either provide the same therapeutic effect or are 
therapeutically equivalent. To better understand how bioequivalence is assessed, a few terms 
should be introduced. If two drug products contain identical amounts of the same active 
ingredient, they are pharmaceutical equivalents. If, instead, two drug products both contain an 
identical therapeutic moiety, but not necessarily in the same amount or dosage form or as the 
same salt or ester, they are identified as pharmaceutical alternatives to each other. Two drug 
products are identified as bioequivalent if (1) they are either pharmaceutical equivalents or 
pharmaceutical alternatives and (2) their rates and extents of absorption do not show a significant 
difference when administered at the same molar dose of the therapeutic moiety under similar 
experimental conditions (Chow and Liu 1992). This work will focus on the statistical methods 
used in the latter of these two criteria. In general, bioequivalence studies focus on the 
comparison ofbioavailabilites using measurements ofthe blood concentration-time profile, such 
as the extent of drug absorption as measured by the Area Under the Curve (AUC), the maximum 
drug concentration (Cmax), and the time required to reach the maximum drug concentration (T max) 
(see Figure 1). In the United States, standards for bioequivalence studies are set by the U.S. Food 
and Drug Administration (FDA). 
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Traditionally, simple measures such as average bioequivalence (ABE) have been used to satisfy 
FDA standards ofbioequivalence. Suppose two drug products are to be compared. Let R be the 
reference formulation and T the test formulation. These could be two formulations of the same 
drug or two different drug products. ABE is declared if the mean values ofpharmacokinetic 
parameters measured after administration of the two formulations are sufficiently close; that is, 
ABE is declared if 
(1) 
where Ilr and IlR are the means of the response variables Y T and Y R for the drug products T and 
R, respectively, and !:J. is determined by the drug regulatory bodies, such as the FDA. When 
using AUC to measure bioavailability, equation (1) usually represents bioequivalence on the 
logarithmic scale. If 1'r and 1'R are the mean bioavailabilities of the test and reference drug 
products on the original scale, the bioequivalence may be defined as 
exp( -!:J.) <:; (2) 
A typical choice for exp(!:J.) is 1.25. Thus, the means are generally taken to be sufficiently close 
if a 90% confidence interval for the ratio of the observed means of the formulations Rand T fall 
within a bioequivalence limit, generally 80 to 125(% for the ratio of the formulation averages. 
(Note: 0.80 is the reciprocal of 1.25.) 
Anderson and Hauck (1990) noted limitations of ABE and proposed using popUlation 
bioequivalence (PBE) and individual bioequivalence (IBE). For example, when a patient begins 
a new drug therapy and two formulations are available, the choice does not matter, at least with 
respect to bioavailability, if the distributions of between-subject responses for the two 
formulations are sufficiently close. Now ABE is based on a comparison of the mean responses 
and ignores other features of the distributions, such as the variance. Population bioequivalence 
(PBE) or prescribability is claimed if the response distributions of the formulations Rand Tare 
sufficiently similar. For some random variables, including normal ones, the distribution is 
determined by the first two moments. Thus measures of PBE have included comparisons of both 
the means and variances 
Let Y i be the response associated with formulation i. For two drug products to be PBE, Schall 
and Luus (1993) suggested that the between-subject differences Y r - Y Rand Y R - Y R' should be 
sufficiently close; that is, the distribution of the between-subject difference ofbioavailabilities in 
subjects receiving the test and reference drug products should be sufficiently close to the 
between-subject difference ofbioavailabilities in subjects who receive the reference drug 
product. Based on this concept, they suggested two measures ofbioequivalence. The first claims 
PBE if 
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or equivalently, if 
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(3) 
(4) 
where 0BT 2 and 0BR 2 are the between-subj ect variances of Y T and Y R' respectively, and I:1p is the 
bioequivalence limit. The FDA (1999) draft guidelines recommend that the criterion in 
equations (3) and (4) be standardized giving the mean-squared difference criterion: 
2 2 
max( a BR' aBO) 
(5) 
where OB02 is a specified constant and 8p is the bioequivalence limit on the standardized scale. 
The left-side of equation (5) has the form 
ABE limit 2 + variance factor 
variance 
(6) 
This led the FDA (1999) in its draft guidelines to suggest taking 
(7) 
The (In 1.25)2 is the square ofthe usual ABE limit. The recommendations are to set Ep = 0.02 
and OB02 = 0.2, leading to 8p = 0.35. 
The second criterion, the probability-based criterion, again uses the between-subject differences 
YT - YR and YR - YR' and declares PBE if 
P1IYT - YRI s r) - P~IYR - Y~I s r) 2 1:12 (8) 
where r and 1:12 are bioequivalence limits. Schall and Luus (1993) suggested r = In(1.25) and 1:12 
between -20 and -25%. Here 1:12 = -20% is used. 
Even though two drugs may be PBE, the presence of subj ect -by-formulation interaction may 
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cause some patients who have been taking one formulation to have significantly different 
responses if they are switched to the other formulation. This led Anderson and Hauck (1990) to 
introduce the concept of individual bioequivalence (IBE) or switchability. Suppose a patient is 
on the reference formulation. If the distribution of within-subject differences Y T - Y R is 
sufficiently close to that ofthe within-subject differences Y R - Y R', then it does not matter 
whether the patient continues with the references formulation or changes to the test formulation; 
that is, the patient may be switched. 
Schall and Luus (1993) proposed a mean-squared difference criterion and a probability-based 
criterion for assessing IBE that are analogous to those for evaluating PBE. The primary 
difference in the criteria for PBE and IBE is that when considering the differences Y T - Y R and 
Y R - Y R', the PBE criteria use between-subject differences while the IBE criteria use within-
subject differences. Thus, when working with within-subject differences, the mean-squared 
difference criterion for IBE based on equation (3) is 
( ) 2 2 2 2 A 2 IlT - IlR + aD + a WT - a WR :": u,[ (9) 
where aw/ and aw/ are the within-subject variances of Y T and Y R' respectively, aD 2 is the 
subject-by-formulation interaction, and b.1 is the bioequivalence limit. In a manner analogous to 
that in equation (5), equation (9) can be standardized, giving 
2 2 
max( a WR' a wo) 
(10) 
where awo2 is the specified lower threshold for within-subject variance, and 81 is the standardized 
IBE limit. Again noting the relationship to ABE, FDA (1999) suggests 
(In 1.25)2 + E[ 
8[ == ------
2 (11) a wo 
and recommends setting EI = 0.05 and awo2 = 0.2, producing 81 = 0.50. The probability-based 
criterion for IBE may be stated as in equation (8), but the probabilities should now be based on 
within-subject differences instead of the between-subject differences used in assessing PBE. 
The mean-squared difference criterion is recommended in the draft FDA guidelines (FDA 1999), 
but the probability-based criterion is not. In this study, the properties of bootstrap confidence 
intervals for the assessment of PBE and IBE using a 2 x 4 crossover experimental design are 
explored. 
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2. Methods 
The model for a 2 x 4 crossover experimental design is 
Yijkl = 11k + Yikl + 0ijk + Eijkl' i = 1, 2; j = 1, 2, ... , ni; k = R, T; I = 1, 2 (12) 
where YijkJ denotes the response of the jth subject within the ith sequence, receiving the kth 
treatment, in the lth treatment replicate for the subject in sequence i; 11k is the mean response 
from treatment k; YikJ is the fixed effect of replicate 1 on treatment k in sequence i; 0ijk is the 
random effect of the jth subject receiving the kth treatment within the ith sequence; and E ijkJ is the 
random error associated with YijkJ . Assume that the E ijkJ are independently and identically 
distributed as 
(13) 
where aw/ is the within subject variance for treatment k. Note that the assumption of normality 
is not needed for the bootstrap method so a general distribution D is assumed. The random 




where a BR2 and aB/ are the between-subject variances for the reference R and test T 
formulations, respectively; and p is the correlation between the reference formulation R and test 
formulation T responses from sUbjectj. The correlation coefficient p is related to the subject-by-
formulation interaction variance component aD2 as follows: 
(15) 
Note that for model (12), it is assumed that a sufficiently long wash-out period exists between the 
consecutive points in time that either formulation R or T is administered to a subject so that no 
carryover effects are present. 
The statistical hypotheses of interest when evaluating PBE are 
2 2 
max( a BR' aBO) 
(16) 
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versus 
(17) 
Thus, PBE is claimed if the null hypothesis (16) is rejected in favor of the alternative (17). Note 
that the PBE equation (5), consistent with the alternative hypothesis (17), may be written as 
(18) 
Thus, PBE could be declared if the upper limit of an upper one-sided confidence interval on the 
left-side of equation (18) is less than zero. 
Similarly, the statistical hypotheses being tested in evaluating IBE are 
( ) 2 2 (2 2) ).IT -).lR + aD + a WT - a WTR e 
;:: I (19) 
versus 
(20) 
Hence rejection of the null hypothesis (19) in favor of the alternative (20) leads to a conclusion 
of IBE. Also, the IBE equation (10) may be written as 
(21) 
If the upper limit of an upper one-sided confidence interval on the left -side of equation (21) is 
less than zero, IBE can be declared. 
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(23) 
Recall that D.2 = -0.20 = -20%. Thus, if the lower limit of a lower one-sided confidence interval 
on the left-side of equation (8) is greater than -0.20, the null hypothesis (22) may be rejected in 
favor of the alternative (23). If the estimated probabilities are based on between-subject 
differences, PBE is declared. If, instead, they are based on within-subject differences, IBE is 
claimed. 
Bootstrap confidence intervals will be used to set the confidence intervals when testing the 
hypotheses for both PBE and IBE. Three steps are involved in generating a bootstrap confidence 
interval for this setting. First, draw n l bootstrap samples (Y R*' Y T*' Y R*' Y T*) with replacement 
from sample observations (Y R' YT, Y R' YT) in sequence 1 and n2 bootstrap samples (YT*' Y R*' 
YT*, YR') with replacement from sample observations (YT, YR, YT, YR) in sequence 2. The total 
sample size is n = n l + n2• The second step is to calculate the estimates of E(Y T - Y R)2 - E(Y R -
Y R')2 and Pr(IY T - Y RI ~ r) - Pr(IY R - Y R'I ~ r) from the bootstrap sample. Steps one and two are 
repeated N times where N is generally large, say 1000. The final step is to take the 95 th percentile 
of the N bootstrap estimates ofE(Y T - Y R)2 - E(Y R - Y R')2 as the upper bound of a one-sided 95% 
confidence interval for the left-side of equation (18) when working with between-subject 
differences and equation (21) when working with within-subject differences. Similarly, the 5th 
percentile of the estimates ofPr(IY T - Y RI :<;; r) - Pr(IY R - Y R'I ~ r) is taken as the lower bound of 
the one-sided 95% confidence interval for the left-side of equation (8) where separate 
computations are made for between- and within-subject differences .. 
In the above description of the process of setting bootstrap confidence intervals, the need for 
estimates of E(Y T - Y R)2 - E(Y R - Y R')2 and Pr(IY T - Y RI ~ r) - Pr(IY R - Y R'I ~ r) on both the 
popUlation and individual level was mentioned. Estimators for these quantities will now be 
presented. If there is no period effect, an unbiased estimator of the left-side of equation (18) IS 
(24) 
where r; and r; are the sample means of the bootstrap sample values of Y; and Y~ , 
respectively; a~ and a~; are the sample variances of Y; and Y ~ pooled across sequences; 
and 0;* is the sample variance of (Vl - Y ~ ) pooled across sequences. 
When using equation (8) to assess PBE, the two replicates of formulations T and R for each 
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subject were averaged. Thus, n pairs of ( Y; , Y; ) were formed. An unbiased estimator of the 
population quantity on the left-side of equation (8) is then 
1 n n J- - ) 1 n n J- ) --L L l\lr~. - r~1 s r - L L l\lY;i - Y~I s r 
n(n-1)i=lJ*i=1 n(n-l)/2i=lJ=i+l 
(25) 
where 10 Is the indicator function that takes the value 1 if the statement within the parentheses is 
true and 0 otherwise. The period effect was tested for significance and estimated using SAS's 
mixed procedure with the first-order factor analytic variance-covariance structure as suggested in 
the draft FDA (1999) guidelines. Values of Y; and r; were adjusted to eliminate any 
significant period effect, and computations proceeded as described above. 
In considering IBE, an unbiased estimator of the mean-squared difference criterion on the left-
side of equation (8) is 
-l-t[(r;u - r;u) + (r;2i - r;u) + (r;u - r;2i) + (r;2i - r;2i)] 
4n i=l 
1~(* *\2 - -  rRU - rR2i!· 
n i~l 
An unbiased estimator of the left-side of equation (8) for the evaluation ofIBE using the 
probability-based criterion is 
(26) 
If a significant period effect was present, the bootstrap sample values were adjusted to remove 
the period effect as described above when considering the estimate associated with PBE. These 
adjusted values were then used in equations (26) and (27). 
A Monte Carlo study was conducted to study the properties of the mean-squared difference 
criteria and the probability-based criteria for PBE and IBE. Only the 2 x 4 crossover design was 
considered. The two treatments were the reference formulation R and the test formulation T. 
Two sequences were used in each simulated experiment. In sequence 1, the treatments were 
arranged in the order ofRTRT. The treatment order was TRTR in sequence 2. Current interest 
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is in the analysis of the log-transformed response of AUC. Because these values are usually 
normally distributed, the normal distribution was used in simulating both the errors and subject 
effects given in equations (13) and (14). The numbers of subjects per treatment simulated were 
3,5,10,20, and 40. The treatment means for formulations Rand T were both 100. Values of aD 
simulated were 0, 0.01, and 0.1. aWR = aWT'= 0.15 in all cases. aBR = aBT = 0.15, 0.30 were 
simulated. In all cases simulated, the conditions for PBE and IBE were satisfied as described in 
equations (5), (8), and (10). For each combination of the parameters, 100 experiments were 
simulated. A hundred bootstrap samples were drawn from each simulated data set.. The 
simulations were run using The SAS System, Version 8.0. The probability of concluding 
formulations R and T were bioequivalent was estimated based on the proportion of simulated 
samples for which the null hypothesis was rejected. 
3. Results 
The effect of inter-subject variability on the probability of concluding PBE and IBE is illustrated 
in Figure 2. No subject-by-formulation interaction is present (aD = 0). Recall that in all cases, 
the parameters being used should lead to the conclusion ofbioequivalence. As would be 
expected, the probability of concluding either PBE (Figure 2a) or IBE (Figure 2b) increases with 
sample size. For both methods, increasing the between-subject variability led to reduced power. 
In assessing PBE, the mean-squared difference criterion has consistently higher power than the 
probability-based criterion. When aBR = aBT = 0.15, approximately eight subjects per sequence 
are sufficient to ensure at least 80% power for the mean-squared difference criterion whereas it 
takes approximately twelve subjects to achieve this level of power when aBR = aBT = 0.30. In 
contrast, the probability-based criterion requires about 54 and 60 subjects per sequence to attain 
80% power when aBR = aBT = 0.15 and 0.30, respectively. Although the mean-squared difference 
criterion continues to have more power than the probability-based criterion when considering 
IBE, the difference in the two criteria is less than that observed for PBE. For the mean-squared 
difference criterion, fewer than ten subjects/treatment are needed to achieve at least 80% power 
for aBR = aBT = 0.15 or 0.30. The results for the probability-based criterion are somewhat 
confusing as the estimated power is greater for aBR = aBT = 0.30 than for aBR = aBT = 0.15. This 
may be due to either the low number of simulated data sets or the small number N of bootstrap 
samples per data set. Certainly further study is needed to determine whether this observation is 
an anomaly or in fact a property of this criterion. 
The effect of subject-by-formulation interaction on the probability of concluding PBE and IBE is 
illustrated in Figure 3. In all cases, aWR = aWT = 0.15 and aBR = aBT = 0.30. The subject-by-
formulation interaction was varied with aD = 0.0, 0.01, and 0.1. For both PBE and IBE, the 
mean-squared difference criterion consistently had greater power than the probability-based 
criterion. Neither criteria showed a large change in power as aD increased from 0 to 0.01, but 
both showed a major drop in power as aD was increased to 0.1. The drop was especially great 
when assessing PBE. It should be noted that as aD continues to increase, the drugs Rand Tare 
no longer considered either PBE or IBE. Thus, this drop in power is anticipated. 
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4. Discussion 
The power of the mean-squared difference and the probability-based criteria in evaluating PBE 
and IBE for a 2 x 4 crossover design was investigated through a Monte Carlo study. Because 
only 100 data sets were generated for each combination of parameters and 100 bootstrap samples 
were used to set the confidence limits for each data set, the results of this study should be 
considered to be preliminary. However, few simulation studies on bioequivalence trials have 
been reported in scientific journals (Sheiner 1992). More study is needed to provide a full 
understanding of the properties of the statistical methods being used. 
Although the draft FDA (1999) guidelines do not suggest adjusting for significant sequence or 
period effects, those adjustments were made here. The effect of not adjusting these values should 
also be evaluated. The mean-squared difference criteria is presented in the draft guidelines, but 
the probability-based criteria is not. 
The power associated with the mean-squared difference criterion was consistently higher than 
that of the probability-based criterion. One reason for that may have been the -20% threshold 
value that was used in the study. Schall and Luus (1993) noted that "it is more difficult to 
suggest and motivate a bioequivalence range for" the probability-based criteria "because there is 
little experience with statistics of that form." Based on the results of this study, further 
consideration must be given to setting this value before the probability-based criteria can be 
considered suitable alternatives to the mean-squared difference criteria in evaluating PBE and 
IBE. Other bioequivalence criteria, such as the therapy window criterion (Lyer and Chu 2000), 
should also be explored. 
Although subject-by-formulation interaction is not explicitly present in the development ofPBE 
(see equations (5) and (10)), the impact of such interaction on power appears to be present and 
greater for PBE than for IBE. The reason for this is not yet clear. Increases in between-subject 
variability caused a reduction in power for both PBE and IBE. 
Finally, the method of moments was used to estimate the variance components. Other 
approaches, such as REML (Chinchilli 1996, Endrenyl and Tothfalusi 1999), should also be 
explore. 
5. Summary 
Bootstrap confidence intervals were used to evaluate population bioequivalence and individual 
bioequivalence in the context of a 2 x 4 crossover experimental design. Two bioequivalence 
criteria were compared through Monte Carlo simulation: the mean-squared difference criterion 
and a probability-based criterion. The numbers of subjects per treatment simulated were 3, 5, 10, 
20, and 40. The treatment means for formulations Rand T were both 100. Values of the subject-
by-formulation interaction (aD) simulated were 0, 0.01, and 0.1. The within-subject standard 
deviations were aWR = aWT'= 0.15 in all cases. The between-subject standard deviations aBR = 
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aBT = 0.15, 0.30 were simulated. In all cases, the data were normally distributed, and the 
conditions for population and individual bioequivalence were satisfied. For each combination of 
the parameters, 100 experiments were simulated. SAS' s mixed procedure was used to perform 
the analysis of each data set, assuming a first-order factor analytic variance-covariance structure. 
Adjustments were made for significant sequence and period effects. A hundred bootstrap 
samples were drawn from each simulated data set. The probability of concluding formulations R 
and T were bioequivalent was estimated based on the proportion of simulated samples for which 
the null hypothesis was rejected. The power associated with the mean-squared difference 
criterion was consistently higher than that of the probability-based criterion .. Although subject-
by-formulation interaction is not explicitly present in the development of population 
bioequivalence, such interaction appears to affect power, and the effect seems to be greater for 
population than for individual bioequivalence. Increases in between-subject variability caused a 
reduction in power for both population and individual bioequivalence. The current study is 
limited in that only 100 samples were generated for each combination of parameters, and only 
100 bootstrap samples were used to set the confidence limits for each data set. In addition, the 
effects of non-normality, of unequal sample sizes, of assuming different covariance structures, 
and of using other estimation methods (such as REML) were not evaluated. The probability of 
declaring treatments to be either population or individual bioequivalent when in fact they are not 
should also be considered. 
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Figure 1: Common phannacokinetic measurements from the blood concentration-time profile 
used in evaluating bioequivalence are the area under the curve (AVC), Cmax, and Tmax. 
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Figure 2. The effect of inter-subject variance on population (2a) and individual (2b) 
bioequivalence assessment. 
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Figure 3. The effect of subject-by-formulation interaction on population (3a) and individual (2b) 
bioequivalence assessment. 
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